Array Biopharma, Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc

ARRY 8.410

-2.9%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (285)	5/15/2014 10:19:02 AM
From: scaram(o)uche	Read Replies (1) of 321

Thanks, Nigel. If you haven't listened to the BofA-ML presentation, there was up-front discussion. Squarer said that any return of 162 would be, according to contract, accompanied by trailing support for ongoing trials. That would only take LEE011 combo testing through completion of phase II, but it would take 162 for nras mutant melanoma through testing for registration. Anyway...... UGH, regarding market reaction to abstracts. Tough small cap sledding, unless focused on clvs. (cldx doesn't count, outside influence...... :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next